ATYR
USDaTyr Pharma Inc. Common Stock
वास्तविक समय मूल्य
मूल्य चार्ट
मुख्य मीट्रिक्स
बाजार मीट्रिक्स
खुलना
$5.550
उच्च
$5.749
कम
$5.330
मात्रा
2.00M
कंपनी के मौलिक सिद्धांत
बाजार पूंजीकरण
480.2M
उद्योग
जैव प्रौद्योगिकी
देश
United States
ट्रेडिंग आँकड़े
औसत मात्रा
1.63M
एक्सचेंज
NCM
मुद्रा
USD
52-सप्ताह रेंज
संबंधित समाचार
HC Wainwright & Co. Reiterates Buy on aTyr Pharma, Maintains $35 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates aTyr Pharma with a Buy and maintains $35 price target.
aTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD)
Three out of four efzofitimod-treated diffuse SSc-ILD patients showed clinically important improvement based on the modified Rodnan Skin Score (mRSS) assessment at 12 weeks. Efzofitimod was generally safe and well
aTyr Pharma Presents Three Posters on Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference
Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis largely balanced and representative of targeted trial population. Real-world
HC Wainwright & Co. Reiterates Buy on aTyr Pharma, Maintains $35 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates aTyr Pharma with a Buy and maintains $35 price target.
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, May 16, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or "the Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from
संबंधित स्टॉक
अपडेट रहें
मूल्य अलर्ट सेट करें, AI विश्लेषण अपडेट और वास्तविक समय बाजार समाचार प्राप्त करें।